



Sharing jurisdictional case studies and challenges in expanding Reliance

Naoki Morooka Senior General Manager, Medical Regulatory Policy Department, Shimadzu Corporation Vice Division Chair, Regulatory and Safety Division, JIRA BoD member, DITTA 2025/03/10






Overview

- Reliance in conformity assessment for premarket review
- Abridge Pathway
- Capacity Building for Abridge Pathway or Recognition





Conformity Assessment based on Reliance







Conformity Assessment based on Reliance

- In premarket conformity assessment, conformity is verified against EP using standard.
 - ✓ As a Reliance, it is an issue that the interpretation of each provision of EP and the application of standard are different.

How to demonstrate to comply with EP using Standards

→ Reconsider the needs of mapping guidance for EP?

Withdrawn the following mapping guidance standards based on GHTF EP

ISO 16142-1 Medical devices — Recognized essential principles of safety and performance of medical devices — Part 1 General essential principles and additional specific essential principles for all non-IVD medical devices and guidance on the selection of standards

Part 2: General essential principles and additional specific essential principles for all IVD medical devices and guidance on the selection of standards

I request to reconsider the needs for the mapping guidance for EP, then ISO/TC210WG2 conduct the survey to confirm the needs,


The survey results were shared within ISO/TC210.

More analysis is still needed, but more than 80% of respondents indicated the need for mapping. We would like to suggest to develop the mapping and the criteria to IMDRF MC and ISO/TC210WG2





International Reliance of Pre-market Review








Difficulties in negotiation for Bilateral


- Bilateral negotiations to establish the Bridge Pathway using Reliance and Unilateral or Mutual Recognition using Reliance require time for each regulator to understand the content of each other's regulations.
 - The industry is familiar with the content of each other's regulations because it has submitted
 products to both regulators, which can help each regulator to understand the content of each
 other's regulations and reduce the time required to establish the Bridge Pathway and
 Recognition.







International Reliance of Pre-market Review







MDSAP in Japan

2012/Nov.	US,AU,CAN,BR sign off the agreement of MDSAP.
2013/Autum	JAPAN entry into MDSAP scheme as the observer.
2013/Oct.	Release the abstract of MDSAP scheme.
2014/Jan.	Starting evaluation AO, pilot study by the end of 2016.
2015/Jun.	JAPAN became officially MDSAP RAC member.
2016/Jun.	The pilot for accepting MDSAP report in Japan
2017/Jan.	Starting MDSAP officially.
2021/Sep.	The official statement for accepting MDSAP report in Japan

Japanese Industries request MHLW/PMDA to become a member of MDSAP.

- Request for the creation of differential mapping information to improve the efficiency of EU MDR/IVDR combined audit
- Request for the expansion of MDSAP Affiliate members





Capacity Building and Training Model for Reliance e.g APEC CoE program for Medical Device PWA

Steering Committee

CO-CHAMPIONS

- Japan (MHLW / PMDA)
- Korea (MFDS)
- United States (US FDA)

SUB-CHAMPIONS

- Japan (JIRA)
- United States (AdvaMed)


CENTERS OF EXCELLENCE (CoE)

- Sichuan University (SCU), China
- Pharmaceuticals and Medical Devices Agency (PMDA), Japan
- Soonchunhyang University (SCH), Korea
- Taiwan Food and Drug Administration (TFDA), Chinese Taipei
- University of Southern California (USC), United States





Regulatory Model and Foundational IMDRF/GHTF Guidance Doc.







Thank you/Questions